AFT PHARMACEUTICALS
AFT
 End-of-day quote - 11/26 |
|
| 4.8NZD | +2.13% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Pharmaceuticals | |||
| Pharmaceuticals | |||
| Pharmaceuticals - NEC | |||
AFT Pharmaceuticals Limited is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The Company's NasoSURF Nebuliser is in pilot scale production. The Company is focused on conducting clinical for Maxigesic oral dose forms. The Company is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Sales per Business
| 2019 | 2020 | |||
| NZD (in Million) | % | NZD (in Million) | % | |
| Pharmaceutical | 83.65 | 98.3% | 101.42 | 96% |
| Licensing | 1.22 | 1.4% | 3.83 | 3.6% |
| Royalties | 0.255 | 0.3% | 0.356 | 0.3% |
Sales per region
| 2019 | 2020 | |||
| NZD (in Million) | % | NZD (in Million) | % | |
| Australia | 50.30 | 59.1% | 61.43 | 58.2% |
| New Zealand | 26.80 | 31.5% | 30.11 | 28.5% |
| Rest of World | 5.89 | 6.9% | 9.13 | 8.6% |
| Southeast Asia | 2.14 | 2.5% | 4.93 | 4.7% |
Managers
| Name | Title |
| Hartley Atkinson | Chief Executive Officer, Executive Director & MD |
| David Mark Flacks | Chairman |
| Malcolm Tubby | Chief Financial Officer & Secretary |
| Douglas John Wilson | Independent Non-Executive Director |
| Marree Atkinson | Executive Director & Chief of Staff |
| Jon Lamb | Independent Non-Executive Director |
| James S. Burns | Independent Non-Executive Director |
| Anita Baldauf | Non-Executive Director |
| Murray Keith | Marketing Manager |
| Vladimir Ilievski | Manager-Regulatory Affairs |
| Shareholders |
| Name | Equities | % |
| Hartley Atkinson | 1,617,818 | 1.55% |
| Accident Compensation Corp. | 852,002 | 0.81% |
| Guardians of New Zealand Superannuation | 737,134 | 0.70% |
| Jon Lamb | 248,094 | 0.24% |
| Joeri Yvonne Jozef Sels | 220,642 | 0.21% |
| Hamish Atkinson | 190,000 | 0.18% |
| David Mark Flacks | 178,764 | 0.17% |
| Joseph Wallace Carson | 150,000 | 0.14% |
| James S. Burns | 125,417 | 0.12% |
| Malcolm Tubby | 93,892 | 0.090% |
Company contact information
AFT Pharmaceuticals Ltd.
Nielsen House
129 Hurstmere Road, Takapuna
Level 1
Auckland 0622
Phone : +64.800.423.823
Fax : +64.800.423.874
Web : http://www.aftpharm.com
Nielsen House
129 Hurstmere Road, Takapuna
Level 1
Auckland 0622
Phone : +64.800.423.823
Fax : +64.800.423.874
Web : http://www.aftpharm.com
Sector Pharmaceuticals - NEC
| 1st jan. | Capi. (M$) | ||
 | |||
| AFT PHARMACEUTICALS LIMITED | 37.14% | 351 | |
| |||
| JOHNSON & JOHNSON | -1.50% | 378 244 | |
| ROCHE HOLDING AG | -4.41% | 282 585 | |
| PFIZER INC. | -1.59% | 203 048 | |
| NOVARTIS AG | -11.88% | 202 620 | |
| MERCK & CO., INC. | -11.97% | 202 555 | |
| ABBVIE INC. | 17.69% | 183 962 | |
| NOVO NORDISK A/S | 6.40% | 152 415 | |
| BRISTOL-MYERS SQUIBB COMPANY | -2.10% | 142 003 | |
| ASTRAZENECA PLC | 1.85% | 137 013 | |
| ELI LILLY AND COMPANY | 10.13% | 131 228 | |
| AMGEN INC. | -8.61% | 128 258 | |
| SANOFI | -6.03% | 126 012 | |
| GLAXOSMITHKLINE PLC | -21.87% | 91 855 | |
| CHUGAI PHARMACEUTICAL CO., LTD. | 42.95% | 73 525 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | 17.92% | 69 214 | |
| DAIICHI SANKYO COMPANY, LIMITED | 56.60% | 68 978 | |
| BAYER AG | -32.50% | 57 498 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | -15.03% | 55 234 | |
| ASTELLAS PHARMA INC. | -15.08% | 28 729 | |
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 36.49% | 26 384 | |
